Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows
- PMID: 38676447
- PMCID: PMC11405507
- DOI: 10.1210/endrev/bnae009
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows
Abstract
The 6th International Conference, "Controversies in Vitamin D," was convened to discuss controversial topics, such as vitamin D metabolism, assessment, actions, and supplementation. Novel insights into vitamin D mechanisms of action suggest links with conditions that do not depend only on reduced solar exposure or diet intake and that can be detected with distinctive noncanonical vitamin D metabolites. Optimal 25-hydroxyvitamin D (25(OH)D) levels remain debated. Varying recommendations from different societies arise from evaluating different clinical or public health approaches. The lack of assay standardization also poses challenges in interpreting data from available studies, hindering rational data pooling and meta-analyses. Beyond the well-known skeletal features, interest in vitamin D's extraskeletal effects has led to clinical trials on cancer, cardiovascular risk, respiratory effects, autoimmune diseases, diabetes, and mortality. The initial negative results are likely due to enrollment of vitamin D-replete individuals. Subsequent post hoc analyses have suggested, nevertheless, potential benefits in reducing cancer incidence, autoimmune diseases, cardiovascular events, and diabetes. Oral administration of vitamin D is the preferred route. Parenteral administration is reserved for specific clinical situations. Cholecalciferol is favored due to safety and minimal monitoring requirements. Calcifediol may be used in certain conditions, while calcitriol should be limited to specific disorders in which the active metabolite is not readily produced in vivo. Further studies are needed to investigate vitamin D effects in relation to the different recommended 25(OH)D levels and the efficacy of the different supplementary formulations in achieving biochemical and clinical outcomes within the multifaced skeletal and extraskeletal potential effects of vitamin D.
Keywords: Vitamin D Standardization Program (VDSP); calcifediol; calcitriol; cholecalciferol; vitamin D; vitamin D assay.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.
Figures





Similar articles
-
Is calcifediol better than cholecalciferol for vitamin D supplementation?Osteoporos Int. 2018 Aug;29(8):1697-1711. doi: 10.1007/s00198-018-4520-y. Epub 2018 Apr 30. Osteoporos Int. 2018. PMID: 29713796 Review.
-
DOES VITAMIN D METABOLITE MEASUREMENT HELP PREDICT 25(OH)D CHANGE FOLLOWING VITAMIN D SUPPLEMENTATION?Endocr Pract. 2017 Apr 2;23(4):432-441. doi: 10.4158/EP161517.OR. Epub 2017 Jan 17. Endocr Pract. 2017. PMID: 28095046 Clinical Trial.
-
[Vitamin D and calcium in the mirror of clinical evidence].Orv Hetil. 2016 Jul;157(31):1242-7. doi: 10.1556/650.2016.30419. Orv Hetil. 2016. PMID: 27476520 Review. Hungarian.
-
Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT.Arch Osteoporos. 2025 Jun 13;20(1):78. doi: 10.1007/s11657-025-01563-y. Arch Osteoporos. 2025. PMID: 40512300 Free PMC article.
-
Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency.Nutrients. 2020 May 31;12(6):1617. doi: 10.3390/nu12061617. Nutrients. 2020. PMID: 32486496 Free PMC article. Review.
Cited by
-
Association of 25-hydroxyvitamin D with all-cause and cardiovascular mortality among individuals with sarcopenia: evidence from the NHANES 2001-2006.Front Nutr. 2025 May 16;12:1562897. doi: 10.3389/fnut.2025.1562897. eCollection 2025. Front Nutr. 2025. PMID: 40453729 Free PMC article.
-
25-hydroxyvitamin D and parathyroid hormone in new onset sepsis: A prospective study in critically ill patients.Metabol Open. 2024 Jun 15;23:100296. doi: 10.1016/j.metop.2024.100296. eCollection 2024 Sep. Metabol Open. 2024. PMID: 38983450 Free PMC article.
-
Vitamin D testing in pharmacies: Results of a federal screening campaign.Explor Res Clin Soc Pharm. 2025 Mar 25;18:100596. doi: 10.1016/j.rcsop.2025.100596. eCollection 2025 Jun. Explor Res Clin Soc Pharm. 2025. PMID: 40236586 Free PMC article.
-
Hypoparathyroidism: diagnosis, management and emerging therapies.Nat Rev Endocrinol. 2025 Jun;21(6):360-374. doi: 10.1038/s41574-024-01075-8. Epub 2025 Feb 4. Nat Rev Endocrinol. 2025. PMID: 39905273 Review.
-
Nutritional and metabolic modulation of inflammation in critically ill patients: a narrative review of rationale, evidence and grey areas.Ann Intensive Care. 2024 Aug 1;14(1):121. doi: 10.1186/s13613-024-01350-x. Ann Intensive Care. 2024. PMID: 39088114 Free PMC article. Review.
References
-
- Giustina A, Adler RA, Binkley N, et al. Controversies in vitamin D: summary statement from an international conference. J Clin Endocrinol Metab. 2019;104(2):234‐240. - PubMed
-
- Ebeling PR, Adler RA, Jones G, et al. Management of endocrine disease: therapeutics of vitamin D. Eur J Endocrinol. 2018;179(5):R239‐R259. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical